serine (or cysteine) peptidase inhibitor, clade F, member 2
| GO Term | Evidence Code | PMID |
|---|---|---|
| maintenance of blood vessel diameter homeostasis by renin-angiotensin | ||
| acute-phase response | ||
| negative regulation of peptidase activity |
|
|
| negative regulation of plasminogen activation | ||
| negative regulation of plasminogen activation |
| GO Term | Evidence Code | PMID |
|---|---|---|
| cell surface | ||
| collagen-containing extracellular matrix |
| GO Term | Evidence Code | PMID |
|---|---|---|
| protease binding | ||
| protease binding | ||
| endopeptidase inhibitor activity | ||
| serine-type endopeptidase inhibitor activity | ||
| serine-type endopeptidase inhibitor activity |
| DO ID | Disease Name | Source |
|---|---|---|
| DOID:0060601 | alpha-2-plasmin inhibitor deficiency |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.5.0
Last updated: April 6, 2026